The U.S. Supreme Court on Friday agreed to referee a patent tussle between Sandoz Inc. and Amgen Inc. over the marketing of “biosimilar” products.
The two companies filed cross-petitions asking the court to take up the dispute, which centers on provisions of the Biologics Price Competition and Innovation Act that spell out when a biosimilar manufacturer is obliged to provide information about a new product to the company that makes the original. The Amgen-Sandoz case represents the Supreme Court’s first stab at interpreting the law, which affects an increasingly important segment of the pharmaceutical industry.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
